Free Trial
NASDAQ:TERN

Terns Pharmaceuticals (TERN) Stock Price, News & Analysis

Terns Pharmaceuticals logo
$4.23 -0.03 (-0.70%)
As of 07/3/2025 02:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Terns Pharmaceuticals Stock (NASDAQ:TERN)

Key Stats

Today's Range
$4.21
$4.36
50-Day Range
$2.78
$4.26
52-Week Range
$1.87
$11.40
Volume
263,302 shs
Average Volume
1.47 million shs
Market Capitalization
$369.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.63
Consensus Rating
Moderate Buy

Company Overview

Terns Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

TERN MarketRank™: 

Terns Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 577th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Terns Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Terns Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Terns Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Terns Pharmaceuticals are expected to decrease in the coming year, from ($1.19) to ($1.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Terns Pharmaceuticals is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Terns Pharmaceuticals is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Terns Pharmaceuticals has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Terns Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    8.94% of the float of Terns Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Terns Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in Terns Pharmaceuticals has recently increased by 9.19%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Terns Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Terns Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.94% of the float of Terns Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Terns Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in Terns Pharmaceuticals has recently increased by 9.19%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Terns Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Terns Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    10 people have searched for TERN on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Terns Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Terns Pharmaceuticals insiders have bought 5,022.87% more of their company's stock than they have sold. Specifically, they have bought $186,575.00 in company stock and sold $3,642.00 in company stock.

  • Percentage Held by Insiders

    Only 1.50% of the stock of Terns Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    98.26% of the stock of Terns Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Terns Pharmaceuticals' insider trading history.
Receive TERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TERN Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
3 Penny Stocks Wall Street Sees With 243% Upside
See More Headlines

TERN Stock Analysis - Frequently Asked Questions

Terns Pharmaceuticals' stock was trading at $5.54 on January 1st, 2025. Since then, TERN shares have decreased by 23.6% and is now trading at $4.23.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.03.

Terns Pharmaceuticals (TERN) raised $101 million in an IPO on Friday, February 5th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO.

Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Terns Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX).

Company Calendar

Last Earnings
5/08/2025
Today
7/04/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TERN
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.63
High Stock Price Target
$20.00
Low Stock Price Target
$7.50
Potential Upside/Downside
+269.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.85 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.07 per share
Price / Book
1.04

Miscellaneous

Free Float
86,027,000
Market Cap
$369.45 million
Optionable
Not Optionable
Beta
-0.11
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:TERN) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners